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Abstract
Vascular endothelial growth factor A (VEGF-A) regulates many aspects
of vascular function. VEGF-A binding to vascular endothelial growth
factor receptor 2 (VEGFR2) stimulates endothelial signal transduction
and regulates multiple cellular responses. Activated VEGFR2 under-
goes ubiquitination but the enzymes that regulate this post-translational
modiﬁcation are unclear. In this study, the de-ubiquitinating enzyme,
USP8, is shown to regulate VEGFR2 trafﬁcking, de-ubiquitination, prote-
olysis and signal transduction. USP8-depleted endothelial cells displayed
altered VEGFR2 ubiquitination and production of a unique VEGFR2
extracellular domain proteolytic fragment caused by VEGFR2 accu-
mulation in the endosome–lysosome system. In addition, perturbed
VEGFR2 trafﬁcking impaired VEGF-A-stimulated signal transduction in
USP8-depleted cells. Thus, regulation of VEGFR2 ubiquitination and
de-ubiquitination has important consequences for the endothelial cell
response and vascular physiology.
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Vascular endothelial growth factor-A (VEGF-A) is a
potent pro-angiogenic growth factor involved in regulat-
ing angiogenesis (1). VEGF exerts its effects by binding
and activating a family of three vascular endothelial
growth factor receptor tyrosine kinases (VEGFRs), namely
VEGFR1, VEGFR2 and VEGFR3. VEGFR2 (KDR) is the
principal receptor through which VEGF-A transmits its
pro-angiogenic signals in vascular endothelial cells (2,3).
VEGF-A binding to VEGFR2 promotes dimerization and
trans-autophosphorylation of several key tyrosine residues
present within its cytoplasmic kinase domain (1). Upon
activation, VEGFR2 enters the endosome–lysosome
system through incorporation into clathrin-coated
vesicles and trafficking to early endosomal vesicular
compartments (4).
Ubiquitination of VEGFR2 acts as an endosomal sort-
ing signal by binding to the ubiquitin-interacting motif of
ESCRT-0 components, Hrs and STAM (4–6). Internalized
VEGFR2 can recycle back to the plasma membrane or be
committed for lysosomal degradation (6,7). Ubiquitination
is a dynamic proteinmodification that coordinates receptor
trafficking, recycling and degradation (8). Reversibilty of
ubiquitination is credited to the action of de-ubiquitinating
enzymes (DUBs) (8). These enzymes thus play a distinct
but crucial role in receptor tyrosine kinase trafficking and
turnover (8).
DUBs are a superfamily of 91 enzymes that can be sub-
divided into five distinct subfamilies with differing speci-
ficities for the isopeptide bond that links ubiquitin chains
(9). De-ubiquitination of plasma membrane receptors
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facilitates recycling and is essential for maintaining the
free ubiquitin pool upon which receptor trafficking is
dependent. Similar to the co-ordinated but opposing
effects of kinase and phosphatase activity, ubiquitination
is kept in balance by the activity of DUBs (10).
Although it is known that VEGFR2 is recycled from endo-
somes back to the plasma membrane, it is unknown
which DUBs prevent its lysosomal degradation.
Ubiquitin-specific protease Y (UBPY or USP8) is a DUB
be involved in the trafficking of epidermal growth receptor
tyrosine kinase (EGFR) (11–13). USP8 is a cysteine pro-
tease andmember of the ubiquitin-specific protease (UBP)
family of DUB enzymes capable of catalyzing complete
breakdown of both K48- and K63-linked polyubiquitin
into its componentmonomers (11,14,15). USP8 has diverse
roles in membrane trafficking ranging from endosomal
regulation to retrograde transport (11,13). The early endo-
some ESCRT-0 subunit, STAM, is a USP8-binding partner
(16,17). This interaction occurs via the SH3 domain of
STAM and the proline-rich STAM-binding motif in USP8
(17). USP8 depletion inhibits EGFR degradation and
causes accumulation of ubiquitinated proteins on enlarged
endosomes (11,12).
Once internalized cargo has been committed for degrada-
tion, conjugated ubiquitin must be recycled and removed
by endosomal DUBs such as USP8, which also asso-
ciate with the ESCRT-III complex on late endosomes
(8,18). A model was proposed in which USP8 acts further
downstream of early endosomes to recycle ubiquitin after
endosomal sorting and prior to lysosomal sequestra-
tion, suggesting a role in facilitating membrane receptor
degradation (14). USP8 thus functions at two stages of
plasma membrane receptor trafficking: in early endo-
somes via ESCRT-0 interaction or in late endosomes
via ESCRT-III interaction. In this study, we show that
regulation of VEGFR2 trafficking and de-ubiquitination
by USP8 impacts on downstream signal transduction and
proteolysis.
Results
USP8 regulates VEGFR2 trafﬁcking
Previous studies have shown that USP8 depletion causes
EGFR accumulation in early endosomes and inhibits
downstream degradation due to general defects in endoso-
mal sorting (11). USP8 thus seemed a likely candidate for
regulating VEGFR2 trafficking. To test this, we used siRNA
duplexes to deplete USP8 in primary human endothelial
cells prior to VEGF-A stimulation and immunofluo-
rescence analysis (Figure 1A). In control cells treated
with non-targeting siRNA, internalized VEGFR2 was
detected in punctate structures at early (0–15 min) stages
of VEGF-A stimulation (Figure 1A). After VEGF-A stim-
ulation for 60min, VEGFR2 staining was substantially
reduced consistent with ligand-induced degradation
(Figure 1A).
However, in USP8-depleted endothelial cells resting
VEGFR2 was already accumulated in enlarged punc-
tate structures (Figure 1A). This pattern of VEGFR2
distribution continued after VEGF-A stimulation for
60min suggesting accumulation of VEGFR2 within
the endosome-lysosome system (Figure 1A). Persis-
tence of these enlarged, VEGFR2-enriched punctate
structures following VEGF-A stimulation indicated per-
turbed VEGFR2 trafficking and degradation. VEGFR2
accumulation also occurred when cells were treated
with individual USP8 siRNAs to limit off-target effects
(Figure S1, Supporting Information). To quantify distri-
bution of mature VEGFR2 in the endosomal pathway,
USP8-depleted endothelial cells were pre-treated with
cycloheximide (CHX) to block protein synthesis fol-
lowed by VEGF-A stimulation (Figure 1A). Although the
biosynthetic pool of Golgi-localized VEGFR2 was absent
after CHX treatment, mature VEGFR2 still accumulated
in USP8-depleted cells (Figure 1A). Quantification of
VEGFR2 residing in the endosome–lysosome system
upon CHX treatment revealed VEGFR2 levels were 30%
higher in non-stimulated, USP8-depleted cells (Figure 1B).
In addition, VEGFR2 underwent 20%VEGF-A-stimulated
degradation in control cells. Contrastingly, high levels of
accumulated VEGFR2 persisted in USP8-depleted cells,
undergoing only 5% VEGF-A-stimulated degradation
(Figure 1B).
To ascertain the nature of these VEGFR2-enriched struc-
tures, USP8-depleted endothelial cells were stained for
VEGFR2 and an early endosome marker, early endosome
antigen-1 (EEA-1) (Figure 1C). Quantification revealed
increased co-distribution between VEGFR2 and EEA1
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Figure 1: USP8 is essential for VEGFR2 trafﬁcking. A) Endothelial cells transfected with non-targeting or USP8 siRNA,
pre-treated with CHX and stimulated with 25 ng/mL VEGF-A were ﬁxed and processed for immunoﬂuorescence microscopy using
antibodies to VEGFR2 followed by ﬂuorescent species-speciﬁc secondary antibodies (green). Nuclei were stained with DNA-binding dye,
DAPI (blue). Scale bar represents 200 μm. B) Quantiﬁcation of VEGFR2 levels residing in the endosome-lysosome system in endothelial
cells pre-treated with CHX and stimulated with VEGF-A prior to immunoﬂuorescence analysis. C) Endothelial cells transfected with USP8
siRNA and stimulated with 25 ng/mL VEGF-A for 15min were ﬁxed and processed for immunoﬂuorescence microscopy using antibodies
to VEGFR2 (green) and EEA1 (red) followed by ﬂuorescent species-speciﬁc secondary antibodies. Nuclei were stained with DNA-binding
dye, DAPI (blue). Scale bar represents 70 μm. D) Quantiﬁcation of co-distribution between VEGFR2 and EEA1 in endothelial cells treated
with non-targeting or USP8 siRNA and stimulated with VEGF-A prior to immunoﬂuorescence analysis. Errors bars indicated ±SEM
(n≥ 3); p< 0.05 (*), p< 0.0001 (****).
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before and after VEGF-A stimulation in USP8-depleted
cells in comparison to control cells (Figure 1D). In addi-
tion, USP8-depleted cells were co-stained with markers
for the plasma membrane (PECAM1), Golgi (TGN46),
early endosomes (EEA1), late endosomes (CD63) and lyso-
somes (LAMP2) (Figure S2A). Quantification revealed
that VEGFR2 distribution across these other organelles
was minimally affected by USP8 depletion whilst accu-
mulation took place in EEA1-positive early endosomes
(Figure S2B).
VEGFR2 also accumulated in EEA1-positive early endo-
somes when cells were treated with individual USP8
siRNAs to limit off-target effects (Figure S3). In addi-
tion, the enlarged VEGFR2-positive endosomes did not
co-distribute with late endosome marker, CD63, in cells
treated with individual USP8 siRNAs (Figure S4). These
findings confirm that VEGFR2 accumulates in early
endosomes of USP8-depleted endothelial cells. Thus,
USP8 is essential for VEGFR2 trafficking through the
endosome–lysosome system.
USP8 regulates VEGFR2 proteolysis
VEGFR2 proteolysis is regulated by ubiquitination (6,19).
A characteristic feature of VEGFR2 activation is traffick-
ing through the endosome–lysosome system and gener-
ation of a transient ∼160 kDa N-terminal lumenal frag-
ment in endosomes (6). Immunoblotting revealed that
the 160 kDa VEGFR2 proteolytic fragment was gener-
ated in both control and USP8-depleted endothelial cells
(Figure 2A). However, a novel∼120 kDa VEGFR2-derived
proteolytic fragment was also produced in USP8-depleted
cells (Figure 2A). Notably, this VEGFR2-related fragment
was also immunoprecipitated from USP8-depleted cells
(Figures 2E, F and 3A).
The novel 120 kDa VEGFR2-derived proteolytic fragment
was present at very low levels in control cells (Figure 2A,
B). However, levels increased more than threefold upon
USP8 depletion (Figure 2C). Treatment with CHX to
block new protein synthesis did not prevent appearance of
the 120 kDa fragment, confirming that it is derived from
proteolytic cleavage of mature VEGFR2 (Figure 2B, C).
USP8-depleted cells also displayed increased production
of the 160 kDa proteolytic fragment (Figure 2D). Thus,
the 160 kDa VEGFR2 fragment could be a precursor of
the smaller 120 kDa fragment. Alternatively, the 120 kDa
fragment may be a unique proteolytic cleavage product
that is not cleared efficiently due to a block in forward
transport toward the lysosome in USP8-depleted cells.
To resolve the identity of the 120 kDa VEGFR2 fragment
VEGFR1 and VEGFR2 were immunoprecipitated from
USP8-depleted cells followed by immunoblot analysis
with antibodies to the extracellular and cytoplasmic
domains of VEGFR2 (Figure 2E). A VEGFR2 extracel-
lular domain antibody detected all species of VEGFR2
in USP8-depleted cells. In contrast, the cytoplasmic
domain antibody only detected full length immature
and mature VEGFR2 (Figure 2E). Thus, similar to the
160 kDa fragment, the 120 kDa VEGFR2 cleavage product
is N-terminal. These findings suggest that USP8 is vital
for efficient clearance of VEGFR2 proteolytic cleavage
products.
USP8 regulates VEGFR2 de-ubiquitination
VEGF-A binding programs VEGFR2 ubiquitination,
endocytosis and proteolysis (4,6,19). De-ubiquitination
is required to divert internalized VEGFR2 away from
lysosomal degradation and towards recycling (8). Based
on the above findings, one possibility is that perturbed
VEGFR2 endosome–lysosome trafficking is linked to
altered VEGFR2 ubiquitination status in USP8-depleted
cells. To assess VEGFR2 ubiquitination in control and
USP8-depleted cells, VEGFR2 immunoprecipitates were
probed by immunoblotting using K48- and K63-linked
polyubiquitin-specific antibodies or a pan-ubiquitin
antibody (Figure 3A). In control cells, VEGFR2 ubiq-
uitination peaked 15min after VEGF-A stimulation
(Figure 3A). Accumulation of proteolytic cleavage prod-
ucts in USP8-depleted cells reduced levels of mature
VEGFR2 and resulted in lower levels of ubiquitinated
full-length receptor (Figure 3A). However, a lower
molecular weight species of ubiquitinated VEGFR2
that corresponds to the 160 kDa proteolytic fragment
and represents increased and persistent ubiquitination
of this cleavage product was evident in USP8-depleted
cells (Figure 3A, arrowhead). USP8 depletion increased
levels of this K48- and K63-linked polyubiquitinated
species of VEGFR2. Unlike in control cells, this species
of ubiquitinated VEGFR2 was present in non-stimulated
cells and persisted over a time course of VEGF-A stim-
ulation (Figure 3A). Quantification of immunoblot data
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Figure 2: USP8 depletion promotes generation of a novel 120 kDa VEGFR2 proteolytic cleavage fragment. Endothelial
cells transfected with non-targeting or USP8 siRNA were treated with 25 ng/mL VEGF-A (A) or 20 μg/mL CHX and 25 ng/mL VEGF-A
(B), lysed and immunoblotted with antibodies against VEGFR2. Quantiﬁcation of 120 kDa (C) or 160 kDa (D) VEGFR2 fragment levels
in endothelial cells transfected with non-targeting or USP8 siRNA and treated with 20 μg/mL CHX and 25 ng/mL VEGF-A. E) VEGFR1
or VEGFR2 were immunoprecipitated from endothelial cells transfected with non-targeting or USP8 siRNA and immunoblotted with
antibodies to the extracellular and cytoplasmic domains of VEGFR2 (F) or run alongside marker ladders to conﬁrm band size. Numbered
arrowheads denote the 160 kDa VEGFR2 fragment (1) and the novel 120 kDa VEGFR2 fragment (2). Error bars denote ±SEM (n≥ 3);
p< 0.05 (*), p< 0.01 (**).
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Figure 3: USP8 regulates VEGFR2 de-ubiquitination.
A) Endothelial cells transfected with non-targeting or USP8
siRNA were treated with 25 ng/mL VEGF-A and lysed. VEGFR2
was immunoprecipitated and immunoblotted for its ubiquitina-
tion status using antibodies against K48-linked polyubiquitin,
K63-linked polyubiquitin and pan-ubiquitin. Arrowheads denote
the species of ubiquitinated VEGFR2 present at higher levels in
USP8-depleted cells. B) Quantiﬁcation of ubiquitinated VEGFR2
levels in endothelial cells transfected with non-targeting or USP8
siRNA and treated with 25 ng/mL VEGF-A. Error bars denote
±SEM (n≥ 3); p< 0.001 (***).
showed that whereas ligand-stimulated VEGFR2 ubiq-
uitination displayed a characteristic peak and decline,
under conditions of USP8 depletion VEGFR2 ubiqui-
tination persisted (Figure 3B). One possibility is that
reduced de-ubiquitination of accumulated VEGFR2 in
USP8-depleted cells increased susceptibility to proteolysis.
Thus, proteolytic cleavage products remain ubiqui-
tinated and accumulate in early endosomes. These
data suggest that USP8 is a key regulator of VEGFR2
de-ubiquitination.
VEGF-A-stimulated VEGFR2 signal transduction
is perturbed by USP8 depletion
VEGF-A stimulates multiple signal transduction pathways
in endothelial cells (20) that regulate many cellular
responses (21). Furthermore, VEGF-A-stimulated
signal transduction is dependent on positional loca-
tion of VEGFR2 at the plasma membrane or within
endosome-related compartments (6,20,22). However,
the role of the ubiquitination/de-ubiquitination cycle in
RTK signal transduction is unclear. Perturbed VEGFR2
endosomal trafficking caused by USP8 depletion could
modulate endosome-linked signal transduction. Con-
trol or USP8-depleted endothelial cells were subjected
to a time course of VEGF-A stimulation followed by
immunoblot analysis to assess VEGFR2 activation and
downstream signal transduction (Figure 4A). VEGF-A
binding causes autophosphorylation of VEGFR2 cyto-
plasmic residue Y1175, creating a key-binding site for
downstream effectors (20). Quantification of immunoblot
analysis revealed VEGFR2-pY1175 levels were ∼60%
reduced in USP8-depleted endothelial cells (Figure 4B).
VEGF-A-stimulated activation of the master regulator
and serine/threonine protein kinase, Akt, was ∼90%
reduced in USP8-depleted cells (Figure 4C). In addition,
VEGF-A-stimulated activation of the mitogen activated
protein kinase (MAPK) pathway involving ERK1/2 was
∼60% reduced in USP8-depleted cells (Figure 4D). Inter-
estingly, USP8 depletion did not significantly affect plasma
membrane-associated phosphorylation and activation of
p38 MAPK or PLCγ1 (Figure 4E, F). USP8 activity thus
modulates VEGF-A-stimulated Akt and ERK1/2 activa-
tion but does not affect other VEGFR2-associated signal
transduction pathways.
Levels of mature, full-length VEGFR2 appear reduced
in USP8-depleted cells (Figure 4A) yet VEGFR2 is
accumulated in early endosomes (Figure 1A). VEGFR2
proteolysis in early endosomes generates 120 and 160 kDa
N-terminal fragments. Proteolytic cleavage products
of mature VEGFR2 accumulate in early endosomes of
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Figure 4: USP8 depletion inhibits VEGF-A-stimulated VEGFR2 signal transduction. A) Endothelial cells transfected with
non-targeting or USP8 siRNA were treated with 25 ng/mL VEGF-A, lysed and immunoblotted for phospho-VEGFR2 (Y1175),
phospho-Akt (S473), phospho-ERK1/2 (T202/Y204) phospho-p38 MAPK (T180/Y182) and phospho-PLCγ1 (Y783). Quantiﬁcation of
phospho-VEGFR2 (B), phospho-Akt (C), phospho-ERK1/2 (D), phospho-p38 MAPK (E), phopho-PLCγ1 (F) and VEGFR2 (G) levels in
endothelial cells transfected with non-targeting or USP8 siRNA. Numbered arrowheads denote mature VEGFR2 (1) and proteolytic
VEGFR2 fragments (2). Errors bars indicated ±SEM (n≥ 3); p< 0.01 (**), p< 0.0001 (****).
USP8-depleted cells after failure to reach a degradative
compartment thus causing an overall increase in total
VEGFR2 levels (Figure 4G).
VEGFR2 plasma membrane dynamics
In USP8-depleted endothelial cells non-stimulated
VEGFR2 displayed accumulation in early endosomes
(Figure 1A). Reduced VEGFR2 availability at the plasma
membrane could thus diminish response to exoge-
nously added VEGF-A. To investigate this possibility,
we used cell surface biotinylation to compare plasma
membrane VEGFR2 pools in control and USP8-depleted
cells (Figure 5A). Quantification revealed little difference
in non-stimulated, plasma membrane VEGFR2 levels
between control and USP8-depleted cells (Figure 5B).
Furthermore, USP8 depletion had little effect on relative
VEGFR2 levels at the plasma membrane over a 60min
time course of VEGF-A stimulation.Thus, reduced plasma
membraneVEGFR2 availability did not account for dimin-
ished VEGF-A-dependent Akt and ERK1/2 activation
(Figures 4C, D and 5B). Monitoring peak VEGFR2-Y1175
phosphorylation at the plasma membrane also revealed
little difference between control and USP8-depleted cells
(Figure 5C). Thus, inhibition of VEGFR2 phosphoryla-
tion (Figure 4B) in USP8-depleted cells likely represents
an effect on the total VEGFR2 pool which continues to
be phosphorylated after internalization. These findings
suggest that USP8 does not regulate plasma membrane
VEGFR2 levels and subsequent activation at the cell
surface.
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Figure 5: USP8 depletion does not affect VEGFR2 levels or activation at the plasma membrane. A) Endothelial cells
transfected with non-targeting or USP8 siRNA were treated with 25 ng/mL VEGF-A, cell surface biotinylated and lysed. Biotinylated
proteins were isolated and immunoblotted using antibodies against phospho-VEGFR2 (Y1175) and VEGFR2. Quantiﬁcation of cell
surface VEGFR2 (B) or phospho-VEGFR2 (C) levels over a time course of VEGF-A stimulation in endothelial cells transfected with
non-targeting or USP8 siRNA. Error bars denote ±SEM (n≥ 3).
VEGFR2 accumulates in early endosomes in USP8-
depleted cells, yet, plasma membrane levels are unaf-
fected (Figures 1B, 5B). One possibility is that plasma
membrane VEGFR2 is replenished by newly synthe-
sized receptor. To test this, we used biotinylation to
compare plasma membrane and internal VEGFR2 pools
in control and USP8-depleted cells treated with CHX.
Biotinylated plasma membrane proteins were isolated and
internal VEGFR2 was immunoprecipitated followed by
immunoblot analysis (Figure 6A). Quantification revealed
that levels of internal VEGFR2 were significantly higher
in USP8-depleted cells after accumulation in early endo-
somes, while plasma membrane VEGFR2 was unaffected.
Upon CHX treatment, cell surface VEGFR2 levels were
significantly reduced in USP8-depleted cells (Figure 6B).
Thus, VEGFR2 that accumulates in early endosomes fol-
lowing cleavage into proteolytic fragments is replenished
at the cell surface by the biosynthetic pool of receptor.
Discussion
In this study, we show that USP8 plays a key role in
VEGFR2 trafficking and proteolysis in the endosome–
lysosome system. In this model, sustained VEGFR2 ubiq-
uitination in the absence of USP8 promotes generation of
a novel 120 kDa VEGFR2 proteolytic fragment (Figure 7).
In addition, USP8-mediated de-ubiquitination and traf-
ficking of VEGFR2 is linked to spatio-temporal control of
VEGF-A-stimulated signal transduction (Figure 7).
Our conclusions are based on four lines of evidence.
First, USP8 depletion leads to VEGFR2 accumulation
within an endosome-like compartment that also con-
tains the early endosome marker, EEA-1. Second, the
appearance of a novel ∼120 kDa VEGFR2-derived pro-
teolytic fragment indicates the existence of a sequence
of compartmental-specific machinery that regulates
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Figure 6: Plasma membrane
VEGFR2 is replenished by
newly synthesized receptor
in USP8-depleted cells. A)
Endothelial cells transfected with
non-targeting or USP8 siRNA
were treated with 10 μg/mL
CHX, cell surface biotinylated
and lysed. Biotinylated proteins
were isolated and the internal
VEGFR2 pool immunoprecipitated
from the supernatant followed
by immunoblot analysis using
antibodies against VEGFR2. B)
Quantiﬁcation of VEGFR2 levels in
cells transfected with non-targeting
or USP8 siRNA and treated with
10 μg/mL CHX. Numbered arrow-
heads denote mature VEGFR2 (1)
and proteolytic VEGFR2 fragments
(2). Error bars denote ±SEM
(n≥ 3); p< 0.05 (*).
VEGFR2 proteolysis. Depletion of USP8 is marked by
aberrant VEGFR2 ubiquitination and turnover, hall-
marks of perturbed ubiquitination and sorting in the
endosome–lysosome system. Whereas ERK1/2 and Akt
signaling is inhibited byUSP8 depletion, other signal trans-
duction pathways are unaffected. The temporal sequence
of events in this pathway suggests that ubiquitination and
de-ubiquitination are closely associated with endosomes
and have major implications for cellular decision making
processes.
Endosomal DUBs are postulated to remove ubiquitin
chains on membrane ‘cargo’ and thus prevent terminal
degradation in lysosomes. Previous work reported that
USP8 depletion severely inhibits EGFR degradation (11).
Ubiquitinated EGFR accumulated in EEA1-positive endo-
somes caused by failure to reach a terminal degradative
compartment (11). Other work also supported the view
that EGFR down-regulation is USP8-dependent (12).
Our study now shows that a different RTK, VEGFR2,
accumulates in early endosomes of USP8-depleted cells.
It is likely that both full-length and partially proteol-
ysed VEGFR2 accumulates in these endosomes upon
USP8 depletion.
Ubiquitin-linked enzyme activity of DUBs plays vital
roles in RTK trafficking (23). USP8 modulates EGFR
trafficking by regulating STAM de-ubiquitination on early
endosomes (11). STAM protection from proteasomal
degradation facilitates forward movement of ubiquitinated
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Figure 7: Regulation of VEGFR2 trafﬁcking, signaling
and proteolysis by USP8. Sustained VEGFR2 residence and
ubiquitination in early endosomes leads to proteolysis that gener-
ates 160 and 120 kDa VEGFR2 fragments in USP8-depleted cells.
The 160 kDa fragment remains ubiquitinated and both VEGFR2
cleavage products accumulate in early endosomes due to an indi-
rect effect of USP8 depletion on the ESCRT-0 trafﬁcking machin-
ery. Both reduced de-ubiquitination and enhanced proteolysis
of accumulated VEGFR2 down-regulate endosome-linked signal
transduction.
receptors through the endosome–lysosome system. USP8
depletion causes almost complete STAM degradation and
hinders further trafficking of cargo proteins (14). Our
studies also lead to the conclusion that USP8 regulates
endosomal machinery (e.g. ESCRT-0) that is essential
for onward trafficking of activated VEGFR2 through the
endosome–lysosome system.
VEGFR2 localization in early endosomes is linked to
subsequent 26S proteasome-dependent proteolysis and
production of a 160 kDa proteolytic fragment (6). Further-
more, production of the 160 kDa fragment has been linked
to down-regulation of VEGFR2 endosomal signaling (6).
This study shows that USP8 depletion is linked to genera-
tion of a novel 120 kDa proteolytic fragment derived from
mature plasma membrane VEGFR2. We postulate that
the 230 kDa mature VEGFR2 protein undergoes sequen-
tial proteolysis in the endosomal network into 160 and
120 kDa extracellular domain fragments. These VEGFR2
fragments could also be individual cleavage products that
remain trapped in early endosomes and inaccessible to
lysosomal degradation due to disruption of ESCRT-0
components and endosome–lysosome delivery upon
USP8 depletion. Another possibility is that an imbalance
in the levels of hydrolases as a result of USP8 depletion
promotes increased VEGFR2 processing and release of the
extracellular domain within early endosomes.
USP8 regulates de-ubiquitination of EGFR/ErbB1 and
ErbB2 (11,15,24). We now provide evidence that USP8
de-ubiquitinates VEGFR2. Whereas VEGFR2 ubiquiti-
nation showed a ligand-dependent peak and decline in
control cells, ubiquitination of the 160 kDa VEGFR2 pro-
teolytic fragment persisted over a time course of VEGF-A
stimulation in USP8-depleted cells.
Reduced VEGFR2 de-ubiquitination upon USP8 deple-
tion did not promote increased lysosomal degradation
due to the indirect effect of USP8 depletion on the traf-
ficking machinery causing accumulation of ubiquitinated
VEGFR2 in early endosomes. This ubiquitinated VEGFR2
was susceptible to proteolysis which reduced levels of
full-length receptor but caused accumulation of cleavage
products in the endosome–lysosome system. VEGFR2
proteolytic fragments of 160 and 120 kDa thus accumu-
lated in early endosomes causing an overall increase in total
VEGFR2 levels.
Lys48 (K48)-linked polyubiquitin chains are associated
with proteasomal degradation while Lys63 (K63)-linked
chains are associated with membrane receptor traffick-
ing and targeting in the endosome–lysosome system
(25,26). Our finding that increased levels of both K48-
and K63-linked polyubiquitin are present on VEGFR2
upon USP8 depletion agrees with other studies that USP8
removes both such polyubiquitin chains from protein
susbtrates (14).
VEGFR2 signal transduction is postulated to be location
dependent with different outcomes at the plasma mem-
brane versus endosomes (22). A requirement for USP8 was
evident in VEGF-A-stimulated ERK1/2 and Akt activation
but not in p38 MAPK and PLCγ1 activation.This outcome
could be linked to perturbed VEGFR2 localization in
endosomes while plasma membrane dynamics are unaf-
fected due to replenishment from the biosynthetic pool
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in USP8-depleted cells. Other studies have also linked
activated VEGFR2 residence in endosomes to ERK1/2
(6,20,22,27,28) and Akt (20,22,27,29) activation. One pos-
sible explanation is that activated VEGFR2 must undergo
USP8-mediated de-ubiquitination on early endosomes as a
pre-requisite for engagement with ERK1/2 and Akt-linked
signal transduction machinery.
Our model proposes that sustained VEGFR2 residence
and ubiquitination in early endosomes leads to proteol-
ysis that generates 160 and 120 kDa VEGFR2 fragments
in USP8-depleted cells (Figure 7). Although the 160 kDa
fragment remains ubiquitinated, both VEGFR2 cleavage
products accumulate in early endosomes because of the
indirect effect of USP8 depletion on trafficking machinery.
Both reduced de-ubiquitination and enhanced proteolysis
of accumulated VEGFR2 down-regulate endosome-linked
signal transduction (Figure 7).
USP8 is required for efficient VEGFR2 trafficking,
de-ubiquitination, signal transduction and proteolysis.
This study emphasizes plasma membrane receptor ubiq-
uitination and de-ubiquitination is more complex than a
simple system for mediating degradation in lysosomes.
Modulation of VEGFR2 ubiquitination status could pro-
vide a new and alternative therapeutic strategy to target
disease states that display aberrant angiogenesis.
Materials and methods
Cell culture and materials
Human umbilical vein endothelial cells (HUVECs) were isolated and
cultured as previously described (30,31).The following reagents were pur-
chased: goat anti-VEGFR2 (R&DSystems), rabbit anti-phospho-VEGFR2
(Y1175), rabbit antibodies to native and phosphorylated c-Akt (S473),
PLCγ1 (Y783) and p38 (T180/Y182), rabbit anti-ERK1/2, mouse
anti-phospho-ERK1/2 (T202, Y204), rabbit anti-USP8 (Cell Sig-
naling Technologies), rabbit anti-TGN46, mouse anti-EEA1 (BD
Biosciences), mouse anti-CD63 (AbCam), mouse anti-α-tubulin, mouse
anti-PECAM1, mouse anti-transferrin receptor (TfR) (Santa Cruz
Biotechnology), mouse FK2 anti-ubiquitin (Affiniti Research Prod-
ucts), rabbit Apu2 anti-K48-linked ubiquitin (Millipore), rabbit Apu3
anti-K63-linked ubiquitin (Millipore), HRP-conjugated secondary
antibodies (PerBio Sciences), AlexaFluor-conjugated secondary antibod-
ies (Invitrogen), endothelial cell growth medium (ECGM) (PromoCell),
non-targeting and USP8 siGENOME SMARTpool siRNA duplexes
(Dharmacon, GE Healthcare) and recombinant human VEGF-A165a
(Genetech Inc.).
Immunoblotting and immunoﬂuorescence
HUVECs were serum starved in MCDB131 (Life Technologies) for 2 h
prior to stimulation with 25 ng/mL VEGF-A165a for various times and
lysed for immunoblotting or immunoprecipitation analyses. In some
experiments, cells were pre-treated with 10 μg/mL CHX (2 h) prior to
VEGF-A stimulation or with 20 μg/mL CHX at the same time as VEGF-A
stimulation. Lysate preparation and immunoblot analysis were performed
as previously described (30,31). For immunofluorescence analysis, cells
were serum starved and pre-treated with 10 μg/mL CHX for 2 h prior to
stimulation with VEGF-A before being fixed and processed as previously
described (30,31). Images were acquired using an Evos-fI inverted digital
microscope (Life Technologies) or a wide-field deconvolutionmicroscope
DeltaVision (Applied Precision Inc.). Relative co-distribution was quan-
tified using NIH Image J (http://rsb.info.nih.gov/ij/).
Immunoprecipitation
HUVECs were serum starved for 2 h prior to VEGF-A stimulation, lysed
in buffer (150mMNaCl, 50mMTris–HCl, pH7.4, 0.1% SDS, 0.5% sodium
deoxycholate, 2mM EDTA, 1% NP-40, 50mM NaF, 1mM PMSF and
10mM iodoacetamide) and incubated with 1 μg/mL goat anti-VEGFR2
for 2 h. Immune complexes were captured using Protein G-agarose beads
before SDS-PAGE and immunoblot analyses.
Cell surface biotinylation
HUVECs were serum starved for 2 h prior to VEGF-A stimulation,
washed in ice-cold PBS and cell surface biotinylation carried out by
incubation with 0.25mg/mL biotin (in 2mM CaCl2, 2mM MgCl2, PBS)
for 45min. Cells were then washed in TBS to quench biotinylation
and lysed in buffer (1% NP-40, 50mM Tris–HCl, pH 7.5, 150mM
NaCl, 1 mM PMSF). Biotinylated cell surface proteins were isolated
using NeutraAvidin-agarose beads (ThermoFisher) before SDS-PAGE
and immunoblotting.
siRNA reverse transfection
HUVECs were reverse transfected in 6- or 96-well plates with siRNA
duplexes as follows.
20 nM non-targeting control siRNA:
5′-UAAGGCUAUGAAGAGAUAC-3′
5′-AUGUAUUGGCCUGUAUUAG-3′
5′-AUGAACGUGAAUUGCUCAA-3′
5′-UGGUUUACAUGUCGACUAA-3′
20 nM USP8 siRNA:
5′-UGAAAUACGYGACUGUUUA-3′
5′-GGACAGGACAGUAUAGAUA-3′
5′-AAAUAAAGCUCAACGAGAA-3′
5′-GGCAAGCCAUUUAAGAUUA-3′
All siRNA duplexes were from ThermoFisher and used according to the
manufacturer’s instructions. Endothelial cells were incubated for 6 h with
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siRNAduplexes using a previously described lipid-based transfection pro-
tocol (30). After 72 h, cells were processed for lysis and immunoblotting
as previously described.
Statistical analysis
Statistical analysis was performed using a one-way analysis of variance
(ANOVA) and Tukey’s post-test analysis for multiple comparisons or
two-way ANOVA followed by the Bonferroni multiple comparison test
using GraphPad Prism software (La Jolla). Significant differences between
control and test groups were evaluated with p-values less than 0.05 (*),
0.01 (**), 0.001 (***) and 0.0001 (****) indicated on the graphs. Error bars
on graphs denote ± standard error of mean (SEM) of results from at least
three independent experiments.
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Figure S1. Individual USP8 siRNAs perturb VEGFR2 trafficking. A)
Endothelial cells transfected with non-targeting or individual USP8 siR-
NAs and stimulated with 25 ng/mL VEGF-A were fixed and processed
for immunofluorescence microscopy using antibodies to VEGFR2 fol-
lowed by fluorescent species-specific secondary antibodies (green). Nuclei
were stained with DNA-binding dye, DAPI (blue). Scale bar represents
200 μm. B) To confirm USP8 depletion, endothelial cells transfected with
non-targeting or individual USP8 siRNAs were lysed and immunoblotted
with antibodies against USP8.
Figure S2. Cellular distribution of VEGFR2 in USP8-depleted cells.
A) Endothelial cells transfected with non-targeting or USP8 siRNA were
fixed andprocessed for immunofluorescencemicroscopy using antibodies
to VEGFR2 (green) and PECAM1, LAMP2, TGN46, EEA1 or CD63 (red)
followed by species-specific secondary antibodies. Nuclei were stained
with DNA-binding dye, DAPI (blue). Scale bar represents 70 μm. B)
Quantification of co-distribution between VEGFR2 and cellular markers
in endothelial cells treated with control or USP8 siRNA. Error bars denote
±SEM (n≥ 3), p< 0.05 (*).
Figure S3. Individual USP8 siRNAs cause VEGFR2 accumulation in
early endosomes. Endothelial cells transfected with individual USP8
siRNAs and stimulated with 25 ng/mL VEGF-A for 15min were fixed
and processed for immunofluorescence microscopy using antibodies to
VEGFR2 (green) and EEA1 (red) followed by fluorescent species-specific
secondary antibodies. Nuclei were stained with DNA-binding dye, DAPI
(blue). Arrows indicate enlarged VEGFR2-positive early endosomes.
Scale bar represents 70 μm.
Figure S4. Individual USP8 siRNAs do not cause VEGFR2 accu-
mulation in late endosomes. Endothelial cells transfected with
individual USP8 siRNAs and stimulated with 25 ng/mL VEGF-A
for 15min were fixed and processed for immunofluorescence
microscopy using antibodies to VEGFR2 (green) and CD63 (red)
followed by fluorescent species-specific secondary antibodies.
Nuclei were stained with DNA-binding dye, DAPI (blue). Arrows
indicate enlarged VEGFR2-positive early endosomes. Scale bar
represents 70 μm.
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